GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lucy Scientific Discovery Inc (NAS:LSDI) » Definitions » EBITDA Margin %

Lucy Scientific Discovery (Lucy Scientific Discovery) EBITDA Margin % : -11,750.00% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Lucy Scientific Discovery EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lucy Scientific Discovery's EBITDA for the three months ended in Dec. 2023 was $-1.18 Mil. Lucy Scientific Discovery's Revenue for the three months ended in Dec. 2023 was $0.01 Mil. Therefore, Lucy Scientific Discovery's EBITDA margin for the quarter that ended in Dec. 2023 was -11,750.00%.


Lucy Scientific Discovery EBITDA Margin % Historical Data

The historical data trend for Lucy Scientific Discovery's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucy Scientific Discovery EBITDA Margin % Chart

Lucy Scientific Discovery Annual Data
Trend Jun21 Jun22 Jun23
EBITDA Margin %
- - -98,871.43

Lucy Scientific Discovery Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - -30,671.43 - -11,750.00

Competitive Comparison of Lucy Scientific Discovery's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Lucy Scientific Discovery's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucy Scientific Discovery's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lucy Scientific Discovery's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Lucy Scientific Discovery's EBITDA Margin % falls into.



Lucy Scientific Discovery EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Lucy Scientific Discovery's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-6.921/0.007
=-98,871.43 %

Lucy Scientific Discovery's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-1.175/0.01
=-11,750.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lucy Scientific Discovery  (NAS:LSDI) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Lucy Scientific Discovery EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Lucy Scientific Discovery's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucy Scientific Discovery (Lucy Scientific Discovery) Business Description

Traded in Other Exchanges
N/A
Address
301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6
Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.
Executives
Richard D Nanula director, officer: Executive Chairman C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Charles B Nemeroff director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Paul Abramowitz director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brian Zasitko officer: Chief Financial Officer C/O LUCY SCIENTIFIC DISCOVERY, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Scott M. Reeves director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Christopher Mcelvany director, officer: President and CEO C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Livio Susin director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brittany Kaiser director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Assad J Kazeminy officer: Chief Scientific Officer C/O LUCY SCIENTIFIC, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6

Lucy Scientific Discovery (Lucy Scientific Discovery) Headlines